In the field of Alzheimer’s disease, no company has suffered more defeat than Lilly. However, this does not prevent the pharmaceutical giant from betting on Alzheimer’s disease assets again and signing a $2 billion deal.
Eli Lilly’s core asset, developed in collaboration with AC Immune, is a drug code-named ACI-3024, which is in the preclinical phase.
AC Immune disclosed on the morning of December 12 that it had a new partnership with Lilly, with a down payment of 80 million Swiss francs, a mid-term mileage of 60 million Swiss francs, and another $1.7 billion in R&D, registration and listing miles. After the product goes on the market, AC Immune can get a low double-digit sales share.
Despite the repeated defeats in the field of Alzheimer’s disease, Lilly has never given up looking for drug candidates that can be used against this disease affecting millions of people.
The current failures have focused on beta amyloid-related targets, and several projects have failed in phase III clinical trials. After Aβ and BACE, Tau protein seems to be the next hot target that everyone is willing to invest. Because in addition to amyloid deposition, the neurofibrillary tangle formed by tau aggregation is one of the classic features in brain tissue of AD patients. The success of treatments targeting tau protein aggregation is even more interesting after numerous therapies for amyloid targeting. Despite the growing research evidence from scientists that a combination of programs is needed to overcome the disease.
The Phase I study of ACI-3024 was launched in the first half of 2019 and was handled by AC Immune.
AC Immune is a Swiss-based company that works closely with Roche to develop the anti-Aβ monoclonal antibody crenezumab for the treatment of Alzheimer’s disease. After a mid-term study failed, the two companies launched a phase III study in early 2017.